JCR Pharmaceuticals Co., Ltd. (JCRRF)
JCR Pharmaceuticals Co., Ltd. operates in the Drug Manufacturers - General industry of the Healthcare sector, headquartered in Ashiya, HY, JP. The stock last traded at $3.32, up 0.00% on the session, giving a market capitalisation of $405.1M. On trailing twelve-month figures it carries a trailing P/E of 75.74, a net margin of 2.0%. Its beta of 0.54 implies it has historically moved less than the broad market.
JCR Pharmaceuticals Co., Ltd., a specialized pharmaceutical company headquartered in Ashiya, Japan, and established in 1975, operates across the entire lifecycle of pharmaceutical products, regenerative medicines, and active drug substances. Its comprehensive activities in Japan encompass research, development, manufacturing, and both the import, export, and sale of these medical items. The company's current therapeutic offerings include several key treatments: GROWJECT, utilized for patients suffering from growth hormone deficiency and short stature. IZCARGO, specifically designed to address Mucopolysaccharidosis type II. Agalsidase Beta BS I.V. Infusion, administered for the management of Fabry disease. TEMCELL HS Inj, employed in the treatment of acute graft-versus-host disease. Furthermore, JCR Pharmaceuticals is actively expanding its pipeline with the development of Epoetin Alfa BS and Darbepoetin Alfa BS Injections, both intended to combat renal anemia. Beyond its pharmaceutical ventures, the firm also provides a selection of medical devices and laboratory instruments.
JCR Pharmaceuticals Co., Ltd. is most often compared with the following Healthcare names: